Mutations in NRAS account for approximately 28% of cutaneous melanoma, of which more than 80% harbor a glutamine-to-leucine substitution (NRASQ61L), thus compromising the intrinsic GTPase activity of NRAS and increasing its GTP-bound form [6]. This evidence concerns the gene NRAS and cutaneous melanoma.